Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT02758067

Comparison of the Effectiveness of Brexpiprazole With That of Risperidone

Interventional, Randomised, Double-blind, Parallel-group, Active-comparator, Flexible-dose Study to Compare the Effectiveness of Brexpiprazole to That of Risperidone in Adult Patients With Schizophrenia

Status
Withdrawn
Phase
Phase 3
Study type
Interventional
Enrollment
0 (actual)
Sponsor
H. Lundbeck A/S · Industry
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

To demonstrate that the effectiveness of brexpiprazole (2-4 mg/day) on quality of life is non-inferior to that of risperidone (4-6 mg/day) in adult patients with schizophrenia.

Conditions

Interventions

TypeNameDescription
DRUGbrexpiprazole2- 4 mg/day, tablets, oral, 28-weeks
DRUGrisperidone4-6 mg/day, tablets, oral, 28-weeks

Timeline

Start date
2016-06-01
Primary completion
2016-06-01
First posted
2016-05-02
Last updated
2016-08-01

Source: ClinicalTrials.gov record NCT02758067. Inclusion in this directory is not an endorsement.